The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..
The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.